Key Takeaways:
UnitedHealth Group has staged an 80% rebound from its 2025 low, but the easy money may already be made.
UnitedHealth Group's medical care ratio improved to 83.9% in the first quarter, down from 84.8% a year earlier, as the insurer prioritized margin recovery over membership growth.
"The historic disciplines and innovations of UnitedHealthcare are rounding back into place," Chief Executive Officer Stephen Hemsley said on the company's first-quarter earnings call.
Adjusted earnings per share of $7.23 beat consensus estimates by about 10%, while revenue rose just 2% year over year to $111.7 billion — a sharp slowdown from the 12% growth the company posted for all of 2025. Management raised its full-year adjusted EPS guidance to more than $18.25, and the company generated $8.9 billion in operating cash flow during the quarter.
The recovery has pushed shares to about $427, up roughly 80% from the 2025 low of $234.60. But with the stock now trading at about 23 times forward earnings — up from 13 times at the trough — and a Department of Justice investigation into Medicare Advantage billing practices unresolved, the risk-reward calculus has shifted.
Margin recovery comes at a cost
UnitedHealthcare, the company's insurance arm, shed 965,000 Medicare Advantage members in the first quarter alone and plans to cut 2.3 million to 2.8 million more through exits of unprofitable contracts. The trade-off is visible in the top line: revenue growth slowed to 2% as the company accepted membership attrition to repair its medical cost ratio.
The improvement in the medical care ratio was driven by a mix of pricing discipline, tighter cost management and favorable reserve development. That last factor, which means past claims came in lower than the company had set aside for, is not a tailwind the company can rely on every quarter.
Two clouds that won't lift
The first is legal. UnitedHealth has disclosed it is responding to both criminal and civil DOJ investigations into how it bills the government for Medicare Advantage members. The probe targets the way insurers document patient diagnoses to set federal reimbursement — a practice at the heart of the Medicare Advantage business model. A federal Office of Inspector General report published June 12 found that UnitedHealth's post-hospital care denial rates ranged from 51 percent to 80 percent across its Medicare Advantage plans, well above peers. Fairview Health Services said the same week it would stop accepting UnitedHealthcare Medicare Advantage in 2027, affecting more than 11,000 patients.
The second is valuation. At 23 times forward earnings, the stock has already repriced much of the recovery story. Two of the most closely watched capital allocators — Warren Buffett's Berkshire Hathaway and David Tepper's Appaloosa Management — both exited or reduced their UnitedHealth positions in the first quarter.
Preliminary 2027 Medicare Advantage rate announcements came in below expectations, adding further pressure to a business model already under regulatory scrutiny. For shares to deliver further upside, the company will need sustained margin improvement, stabilization in membership trends and a favorable resolution to the DOJ probe — none of which is guaranteed.
This article is for informational purposes only and does not constitute investment advice.
